Post by Redcare Pharmacy

🎯 Accelerating growth, improving profitability and raising our guidance for the full year. Today, we announced preliminary trading figures for the first two months of Q2 2026. With strong momentum across both Rx and non-Rx businesses, trading came in stronger than expected, with growth accelerating versus Q1 2026 and remaining consistent throughout the period. Here are the key highlights: - Group revenue increased by 20% YoY quarter-to-date, supported by growth in non-Rx and Rx. - Non-Rx growth in Germany accelerated to 14% YoY quarter-to-date, following 9% in Q1 2026. - Rx Germany continued strong momentum with 57% growth YoY quarter-to-date following 60% in Q4 2025 and 55% in Q1 2026. - Adjusted EBITDA improved YoY, supported by stronger growth and ongoing optimization of marketing mix. “Our trading shows the robustness and momentum of our business, with growth across Rx and non-Rx,” said our CEO Olaf Heinrich. “We continue to gain market share and improve our profitability as we improve CX and execution in general.” This is the new guidance for 2026: - Total revenue growth of 15% to 17% (previously: 13% to 15%) - Non-Rx growth of 10% to 12% (previously: 8% to 10%) - Rx revenue in Germany is now expected to reach EUR 680 to 720 million, representing growth of 35% to 43% (previously: in excess of EUR 670 million) - Adjusted EBITDA margin is now expected between 2.5% and 3.0% (previously: in excess of 2.5%). We look forward to sharing our full Q2 2026 results on July 29. 🗞️ The full press release is available via the link in the comments.